Clear Search sequence regions
Bookmark Forward

QuickView for Vecuronium (compound)


PubChem
Name: Vecuronium Bromide
PubChem Compound ID: 10415356
Description: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
Molecular formula: C34H57N2O4+
Molecular weight: 557.827 g/mol
DrugBank
Identification
Name: Vecuronium Bromide
Name (isomeric): DB01339
Drug Type: small molecule
Description: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
Category: Neuromuscular Nondepolarizing Agents, Nicotinic Antagonists
CAS number: 50700-72-6
Pharmacology
Indication: Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.
Pharmacology: Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.
Mechanism of Action:
Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not releas...
show more »
Biotransformation: 100%
Route of elimination: Fecal (40-75%) and renal (30% as unchanged drug and metabolites)
Half Life: 51–80 minutes
Interactions
Drug interaction:
Cortisone acetateVecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
MethylprednisoloneVecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
ColistimethateColistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
FludrocortisoneVecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
PhenytoinPhenytoin decreases the effect of the muscle relaxant
show more »

Targets


Transporters